Related Experiment Videos
Molecular and clinical heterogeneity in primary hyperoxaluria type 1
1Biochemical Genetics Research Group, MRC Clinical Research Centre, Harrow, Middlesex, UK.
Summary
Primary hyperoxaluria type 1 (PH1) results from alanine:glyoxylate aminotransferase (AGT) deficiency. Studies reveal significant enzyme and clinical heterogeneity in PH1 patients, suggesting broader implications for oxalate stone disease.
Area of Science:
- Biochemistry
- Genetics
- Nephrology
Background:
- Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disease.
- It stems from a deficiency in the liver enzyme alanine:glyoxylate aminotransferase (AGT).
- AGT is crucial for preventing oxalate buildup.
Purpose of the Study:
- To investigate the enzymatic and clinical heterogeneity in PH1 patients.
- To explore the relationship between AGT levels, localization, and disease severity.
- To consider the potential role of AGT deficiency in idiopathic oxalate stone disease.
Main Methods:
- Analysis of liver samples from 59 PH1 patients.
- Assay of AGT catalytic activity.
- Measurement of immunoreactive AGT protein levels.
- Determination of AGT intracellular localization (peroxisomal vs. mitochondrial).
Main Results:
- Significant heterogeneity in AGT activity (0% to 48% of normal) and protein levels was observed.
- Two-thirds of patients had zero AGT activity; one-third had residual activity.
- Patients with AGT activity showed mitochondrial mislocalization; inactive AGT was peroxisomal in most others.
- Clinical presentation varied widely, with no clear correlation between AGT levels and disease severity.
Conclusions:
- PH1 exhibits substantial enzymatic and clinical heterogeneity.
- AGT mislocalization and varying activity levels contribute to disease variability.
- AGT deficiency may underlie a broader spectrum of pathology than previously recognized, including idiopathic oxalate stones.